Amgen Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Amgen Inc. stock analysis AMGN overview
Bullish +75

ONTARIO AND QUEBEC EXPAND PUBLIC COVERAGE OF REPATHA® FOR ELIGIBLE RECENT ACUTE CORONARY SYNDROME PATIENTS

- 🏛️ Amgen Canada announced that Ontario and Quebec have expanded public coverage for Repatha (evolocumab) to treat eligible patients following an acute coronary syndrome (ACS).

- 🦠 In Ontario, reimbursement under the Ontario Drug Benefit program applies to patients within 52 weeks of an ACS who are not meeting cholesterol targets despite standard therapy.

- 👔 Quebec became the first province in Canada to publicly list Repatha for ACS coverage in February, extending eligibility up to 24 months post-event for those failing lipid targets on standard care.

- 📉 Statistics show that 42% of Ontario patients with a history of ACS remain above recommended LDL-C thresholds, while nearly half of Canadian patients at this elevated risk face another cardiovascular event within 3.4 years.

- 👨‍⚕️ Medical experts highlighted that lowering LDL cholesterol is critically important after leaving the hospital to support heart health and reduce the risk of recurrent events.

- 💉 Repatha works by inhibiting PCSK9, a mechanism that increases the liver's ability to remove "bad cholesterol" from the bloodstream to lower cardiovascular risk.

- 🌍 Globally, Repatha is approved in over 70 countries with a patient base of 8.5 million and has been studied in more than 50 clinical trials involving over 57,000 patients.

- ⚠️ The product carries contraindications for hypersensitivity to evolocumab or its ingredients, requiring discontinuation if signs of serious allergic reactions occur.

- 🤰 There is limited data regarding the use of Repatha in pregnant women and nursing women, and it should be discontinued if a patient becomes pregnant.

- 🧒 Efficacy and safety have not been established for pediatric patients under 10 years of age with specific types of hyperlipidemia such as HoFH.

- 🏥 Clinical guidelines recommend additional lipid-lowering treatment when LDL-C remains above 1.8 mmol/L following an ACS to mitigate future event risks.

- 💰 Public funding expansion aims to help more patients access appropriate therapy early after a cardiac event, which is critical for reducing future risk.

- 📜 Full reimbursement criteria and details are available through the Ontario Drug Benefit program or the Régie de l'assurance maladie du Québec (RAMQ) formulary.

- 🚦 The expansion reflects a growing focus on managing cardiovascular risk in the years immediately following an initial acute coronary syndrome event.

Bullish Signals
  • Amgen Canada announced that the Governments of Ontario and Quebec have expanded public reimbursement for Repatha, marking a significant increase in patient access to this life-saving therapy.
  • In Quebec, Repatha was publicly listed on February 4 as the first province to do so, covering eligible patients up to 24 months following an acute coronary syndrome event.
  • Ontario's updated coverage through the Ontario Drug Benefit program now includes eligible patients within 52 weeks of an ACS who are not meeting cholesterol targets despite standard therapies.
  • This expansion is critical given that in Ontario, 42 per cent of patients with a history of an ACS remain above Canadian lipid guideline-recommended LDL-C thresholds despite treatment.
  • Global data supports the efficacy of Repatha, showing it has 8.5 million patients worldwide and is approved in over 70 countries based on studies involving over 57,000 patients.
  • Repatha's mechanism of action increases the liver's ability to remove LDL-C from the bloodstream, directly addressing the high risk of recurrent cardiovascular events following an ACS.
Risk Factors
  • Repatha is not indicated for use in pregnant or nursing women, and data on its safety in these populations is very limited.
  • Efficacy and safety have not been established in pediatric patients under 10 years of age with hyperlipidemia, and data is limited for those aged 10-11 years with HoFH.
  • Hypersensitivity reactions such as rash, urticaria, and angioedema have been reported in clinical use.
  • The drug requires discontinuation in patients with severe renal or hepatic impairment, which limits its applicability to a smaller subset of the patient population.
Full Analysis
Amgen Canada announced on April 7, 2026, that the governments of Ontario and Quebec have expanded public reimbursement coverage for Repatha (evolocumab injection) to include eligible patients following an acute coronary syndrome. In Ontario, through the Ontario Drug Benefit program, coverage now applies to patients within 52 weeks of an ACS event who are not achieving cholesterol targets despite standard lipid-lowering therapies. Previously covered by the drug but now expanded in eligibility, this update aligns with Canadian cardiovascular risk management strategies for recent cardiac events. Quebec had already been a pioneer in this area, listing Repatha for ACS on February 4 as the first province to do so; its updated criteria now cover eligible patients up to 24 months following an event, also focusing on those failing to meet targets on standard therapy. The significance of these expansions is driven by high-risk data showing that patients remaining above LDL-C thresholds after an initial event face a substantially elevated risk of recurrent cardiovascular events or death. Statistics cited indicate that 42% of Ontario patients with ACS history remain above recommended LDL-C levels despite treatment, and nearly half of those above the 1.8 mmol/L threshold will experience another event within 3.4 years. Repatha, a monoclonal antibody inhibitor of PCSK9, is approved globally for over 70 countries and has treated 8.5 million patients in clinical trials involving more than 57,000 individuals. The drug works by increasing the liver's ability to remove LDL cholesterol from the bloodstream, serving as an adjunct to diet and standard therapy for reducing risks of heart attack, stroke, and coronary revascularization. While full reimbursement criteria remain available through provincial formularies like ODB and RAMQ, medical experts emphasize that timely access to these therapies is critical during the high-risk years following a cardiac event.